Iovance Biotherapeutics (NASDAQ:IOVA) Issues Earnings Results

Key Points

• Iovance reported third-quarter revenue of $121.47 million, above analysts’ $115.98 million estimate, and a per-share loss of $0.05—narrower than the expected $0.09 loss. Revenue rose 64.8% year over year, and the company reaffirmed its 2026 revenue guidance of $410 million–$420 million.
• Gross margin reached a record 60%, and Iovance ended the quarter with about $382 million in cash, which management expects to fund operations well into 2029; it did not give a timeline for reaching profitability.
• Lifileucel showed encouraging results in several cancer studies, including a 59.1% response rate in a biomarker-selected lung cancer subgroup. These findings remain investigational, with planned submissions and further trials ahead.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) released its earnings results on Thursday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.04, FiscalAI reports. Iovance Biotherapeutics had a negative return on equity of 30.68% and a negative net margin of 58.20%. The firm had revenue of $121.47 million during the quarter, compared to analysts' expectations of $115.98 million. The business's revenue for the quarter was up 64.8% on a year-over-year basis.

Here are the key takeaways from Iovance Biotherapeutics' conference call:

• Iovance reported record third-quarter revenue of approximately $122 million, up 80% year over year, including about $102 million from AMTAGVI; it reaffirmed 2026 revenue guidance of $410 million–$420 million. The company has treated more than 1,000 commercial patients and expects at least 110 authorized treatment centers by year-end.
• Gross margin reached a record 60%, operating expenses were managed tightly, and Iovance ended the quarter with approximately $382 million in cash, which it expects to fund operations well into 2029. Management said it is moving toward profitability but did not provide a timeline.
• In previously treated non-squamous metastatic lung cancer, lifileucel showed a 24.6% response rate among 69 patients; a biomarker-enriched subgroup had a 59.1% response rate. Iovance plans an sBLA submission in 2027 and is starting a prospective biomarker-selected study, though the findings remain investigational.
• Updated soft tissue sarcoma results showed a 55.6% response rate in five of nine patients with UPS or DDLPS, including two responses ongoing beyond a year. The registrational SARATOGA trial is enrolling, with submissions planned for 2028 or 2029.
• In a phase II frontline melanoma cohort, lifileucel plus pembrolizumab produced a 62.5% response rate, including complete responses in 29.2% of patients; median overall survival had not been reached after more than four years of follow-up. The phase III TILVANCE-301 trial is enrolling to support a potential frontline approval.

Iovance Biotherapeutics Price Performance

IOVA stock traded up $0.30 during midday trading on Friday, hitting $8.04. The company's stock had a trading volume of 12,935,434 shares, compared to its average volume of 15,654,120. The company's fifty day moving average price is $11.37 and its 200 day moving average price is $5.97. Iovance Biotherapeutics has a twelve month low of $2.08 and a twelve month high of $15.37. The stock has a market capitalization of $3.64 billion, a P/E ratio of -15.17 and a beta of 0.88.

Key Stories Impacting Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Iovance reported record third-quarter revenue of about $122 million, beating estimates, while its loss of $0.05 per share was narrower than the expected $0.09. Amtagvi U.S. revenue grew about 77% year over year, gross margin reached a company-record 60%, and management reaffirmed its 2026 revenue outlook. These results point to growing commercial traction and improving economics. Iovance third-quarter results
• Positive Sentiment: Barclays raised its price target from $18 to $19 and kept an “overweight” rating; Citizens JMP raised its target from $8 to $12 and maintained a “market outperform” rating. The upgrades reflect more optimistic analyst views on IOVA’s prospects. Barclays ratings Citizens JMP ratings
• Positive Sentiment: Lifileucel received FDA Fast Track designation following promising sarcoma trial data, potentially supporting development in an additional cancer indication. Lifileucel Fast Track news
• Negative Sentiment: NSCLC results were mixed: the objective response rate was 24.6% across 69 evaluable patients, slightly below a prior interim result. That may temper expectations for this opportunity, although a biomarker-selected subgroup showed a higher 59.1% response rate and a trial is underway. Iovance clinical outlook

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. TD Cowen upped their price objective on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a research report on Monday, August 24th. Citigroup reiterated an "outperform" rating on shares of Iovance Biotherapeutics in a report on Friday, August 7th. Zacks Research raised Iovance Biotherapeutics from a "hold" rating to a "strong-buy" rating in a research report on Monday, October 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Iovance Biotherapeutics in a research note on Tuesday, September 29th. Finally, Barclays boosted their target price on Iovance Biotherapeutics from $18.00 to $19.00 and gave the company an "overweight" rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $13.80.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc NASDAQ: IOVA is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient's tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company's lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.